Vertex Pharmaceuticals Incorporated reported unaudited revenues results for the fourth quarter and year ended December 31, 2016. For the quarter, the company reported total CF product revenues of $453 million.

For the year, the company reported total CF product revenues of $1.68 million.

Vertex provided full-year 2017 net product revenue guidance for KALYDECO and ORKAMBI, as summarized below: KALYDECO: Vertex anticipates full-year 2017 global KALYDECO net product revenues of $690 to $710 million. ORKAMBI: The company anticipates full-year 2017 ORKAMBI net product revenues of $1.1 to $1.3 billion. This range includes an estimate of potential additional European revenues in 2017 that is largely dependent on which European countries complete reimbursement agreements in 2017 and when these agreements become effective. The company expects first-quarter 2017 ORKAMBI net product revenues to be similar to fourth-quarter 2016 ORKAMBI net product revenues.